Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pretomanid
- Development stage
- Approved
- Lead developer
- TB Alliance
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Pretomanid is a small molecule antibiotic in the nitroimidazooxazine class, used as part of a combination regimen with bedaquiline and linezolid for the treatment of pulmonary extensively drug-resistant (XDR) tuberculosis or treatment-intolerant/nonresponsive multidrug-resistant (MDR) tuberculosis in adults. It acts as a prodrug that is metabolically activated by the mycobacterial enzyme deazaflavin-dependent nitroreductase (Ddn), leading to production of nitric oxide and other reactive metabolites. These metabolites inhibit mycolic acid biosynthesis under aerobic conditions, disrupting cell wall formation, and act as respiratory poisons under anaerobic conditions by releasing nitric oxide, which interferes with electron transport and ATP synthesis. Pretomanid was developed by TB Alliance, marking it as one of the first TB drugs developed by a nonprofit organization[1][4][6][7][8].
- Brand names
- Pretomanid
- Other names
- Pretomanid FGK
02
Targets
Dendrin
Beyond the preview
Go deeper on pretomanid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pretomanid.